Onno Teng is professor of Nephrology with a focus on renal autoimmune diseases. He is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC) where he leads the national and European recognized center of expertise for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs). He is chair of the national foundation of Autoimmune Research & Collaboration Hubs (ARCH). Professor Teng has founded a clinical research program for the development of novel treatment strategies in patients with a renal autoimmune diseases including lupus nephritis and ANCA associated vasculitis. Simultaneously, he conducts a translational research program focused on neutrophil extracellular traps, B-cell & plasma cell immunology collectively aimed at innovative immunomonitoring of novel treatment strategies for LuVaCs patients. Professor Teng is actively involved as clinical teacher for Nephrology, Immunology and Basic Physiology & Anatomy in the curriculum of Medicine at the Leiden University. He teaches and supervises medical students for their scientific as well as clinical internships as part of the Medicine curriculum and clinical bedside teaching of the LUMC Internal Medicine residents.

More information about Onno Teng

Onno Teng is professor of Nephrology with a focus on renal autoimmune diseases.

He is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC) where he leads the national and European recognized center of expertise for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs). He is chair of the national foundation of Autoimmune Research & Collaboration Hubs (ARCH).

Professor Teng has founded a clinical research program for the development of novel treatment strategies in patients with a renal autoimmune diseases including lupus nephritis and ANCA associated vasculitis. Simultaneously, he conducts a translational research program focused on neutrophil extracellular traps, B-cell & plasma cell immunology collectively aimed at innovative immunomonitoring of novel treatment strategies for LuVaCs patients.

Professor Teng is actively involved as clinical teacher for Nephrology, Immunology and Basic Physiology & Anatomy in the curriculum of Medicine at the Leiden University. He teaches and supervises medical students for their scientific as well as clinical internships as part of the Medicine curriculum and clinical bedside teaching of the LUMC Internal Medicine residents.

Nephrology

The academic mission is to positively impact the lives of patients with rare and complex renal autoimmune diseases, including Lupus- Vasculitis- and Complement-mediated Systemic autoimmune diseases, by delivering novel treatment strategies to these patients. To do so, the LuVaCs center of expertise is a fundament for several departments in the LUMC to expand their top-referent function and acknowledgment as a center of expertise for rare and complex systemic autoimmune diseases. Thus, this chair will promote multidisciplinary collaborations and care approaches for these rare and complex systemic autoimmune diseases throughout the LUMC. Within the center of expertise patients will be treated and followed  with cutting-edge, innovative treatment strategies as exemplified by compassionate-use programs for refractory patients, clinical trials on novel treatment approaches including new biologicals, small molecules and cell-based immunotherapies. Altogether culminating to nationally and internationally recognized expertise of the LUMC in the field of systemic autoimmune diseases.

Academic carreer

Professor Teng has dedicated his research efforts towards the translation of his knowledge on B-cell immunology to novel treatment strategies for patients with renal autoimmune diseases. He started his training in B-cell immunology at the National Institutes of Health (Bethesda, USA), completed his PhD research on therapeutic targeting of the humoral immune response in rheumatoid arthritis in 2008. After completing his residency in Internal Medicine and Nephrology, he focused as a clinical-scientist on developing novel B-cell targeted treatment strategies and innovative approaches for immunological monitoring strategies for patients with renal autoimmune diseases. During the development of novel treatment strategies, he has successfully established public-private partnerships to establish belimumab as a novel treatment in severe systemic lupus erythematosus (SLE) and lupus nephritis (LN) and conduct an investigator-initiated study into combination treatment belimumab and rituximab for severe SLE/LN, a compassionate use program of avacopan in Dutch AAV patients and demonstrate the efficacy of Voclosporin for severe SLE. In order to establish an academic environment that challenges and facilitates translational research that is clinically relevant to patients, Prof. Teng has initiated and presently coordinates a top-referral center for Lupus-, Vasculitis- and Complement-mediated Systemic Autoimmune diseases (LuVaCs) recognized as a national and European center of expertise. He is Principal Investigator to several single center trials as well as international, collaborative translational studies and is engaged in national and international collaborations to stimulate and improve collaborative research and care for patients with rare, systemic autoimmune diseases. He is chairman of the ARCH AAV National Project, was appointed chairman of the Dutch Working Party for SLE and member of the Dutch nephrology guideline committee for the guideline on the management of pregnancy and kidney diseases. He also served as a member of the European EULAR/ERA-EDTA guideline committee for the management of lupus nephritis and member of the European Immunonephrology Working Group of ERA-EDTA.

Publications